Share:
Share this content in WeChat
X
• Review •
Research progress on the Kaiser score in breast MRI diagnosis
ZHOU Hui  LI Shiguang  LIU Xudong 

DOI:10.12015/issn.1674-8034.2026.11.021.


[Abstract] Breast cancer ranks first in incidence among female malignancies worldwide, and early, accurate diagnosis is a critical prerequisite for improving patient prognosis. The widely used breast imaging reporting and data system (BI-RADS) relies heavily on radiologists' subjective experience, with inherent limitations, including poor interobserver consistency and persistently high rates of unnecessary biopsies in BI-RADS category 4 lesions. The Kaiser score (KS) is a quantitative breast MRI assessment system constructed based on the chi-squared automatic interaction detection decision tree algorithm, integrating five core imaging features to generate an integer score ranging from 1 to 11 with corresponding standardized clinical management recommendations. Multiple studies have confirmed that KS significantly outperforms traditional BI-RADS classification in diagnostic accuracy, interobserver consistency, and reduction of unnecessary biopsies, demonstrating stable diagnostic performance across various clinical scenarios. However, a comprehensive summary and narrative evaluation of the evidence-based diagnostic value, clinical application limitations, and progress in artificial intelligence integration for KS is currently lacking. This article focuses on the scope of application, limitations, and AI integration progress of KS, analyzes current research deficiencies, and explores future development directions, aiming to provide a reference for precision breast lesion imaging differentiation and the standardized clinical promotion of KS assessment protocols.
[Keywords] Kaiser score;breast magnetic resonance imaging;artificial intelligence;evidence-based medicine;diagnostic performance;clinical translation

ZHOU Hui*   LI Shiguang   LIU Xudong  

Radiology Department, the Second People's Hospital of Guiyang City (Jinyang Hospital), Guiyang 550023, China

Corresponding author: ZHOU H, E-mail: 120129871@qq.com

Conflicts of interest   None.

Received  2026-05-14
Accepted  2026-08-10
DOI: 10.12015/issn.1674-8034.2026.11.021
DOI:10.12015/issn.1674-8034.2026.11.021.

[1]
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]
LUBINSKI J, KOTSOPOULOS J, MOLLER P, et al. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations[J]. JAMA Oncol, 2024, 10(4): 493-499. DOI: 10.1001/jamaoncol.2023.6944.
[3]
NIELL B L, JOCHELSON M S, AMIR T, et al. ACR appropriateness criteria® female breast cancer screening: 2023 update[J/OL]. J Am Coll Radiol, 2024, 21(6S): S126-S143 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/41486277/. DOI: 10.1016/j.jacr.2024.02.019.
[4]
EDWARDS S D, LIPSON J A, IKEDA D M, et al. Updates and revisions to the BI-RADS magnetic resonance imaging lexicon[J]. Magn Reson Imaging Clin N Am, 2013, 21(3): 483-493. DOI: 10.1016/j.mric.2013.02.005.
[5]
STROBEL K, SCHRADING S, HANSEN N L, et al. Assessment of BI-RADS category 4 lesions detected with screening mammography and screening US: utility of MR imaging[J]. Radiology, 2015, 274(2): 343-351. DOI: 10.1148/radiol.14140645.
[6]
BALTZER P A T, DIETZEL M, KAISER W A. A simple and robust classification tree for differentiation between benign and malignant lesions in MR-mammography[J]. Eur Radiol, 2013, 23(8): 2051-2060. DOI: 10.1007/s00330-013-2804-3.
[7]
DIETZEL M, BALTZER P A T. How to use the Kaiser score as a clinical decision rule for diagnosis in multiparametric breast MRI: a pictorial essay[J]. Insights Imag, 2018, 9(3): 325-335. DOI: 10.1007/s13244-018-0611-8.
[8]
BALTZER P A T, KRUG K B, DIETZEL M. Evidence-based and structured diagnosis in breast MRI using the Kaiser score[J]. Rofo, 2022, 194(11): 1216-1228. DOI: 10.1055/a-1829-5985.
[9]
ZHOU J J, LIU H R, MIAO H W, et al. Breast lesions on MRI in mass and non-mass enhancement: Kaiser score and modified Kaiser score + for readers of variable experience[J]. Eur Radiol, 2025, 35(1): 140-150. DOI: 10.1007/s00330-024-10922-1.
[10]
KANG Y H, LI Z G, YANG G, et al. Diagnostic performance of the Kaiser score in the evaluation of breast lesions on contrast-enhanced mammography[J/OL]. Eur J Radiol, 2022, 156: 110524 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/36126352/. DOI: 10.1016/j.ejrad.2022.110524.
[11]
RONG X C, KANG Y H, XUE J, et al. Value of contrast-enhanced mammography combined with the Kaiser score for clinical decision-making regarding tomosynthesis BI-RADS 4A lesions[J]. Eur Radiol, 2022, 32(11): 7439-7447. DOI: 10.1007/s00330-022-08810-7.
[12]
HUA B, YANG G, WANG Y, et al. Diagnostic performance of the Kaiser score for contrast-enhanced mammography and magnetic resonance imaging in breast masses: a Comparative Study[J]. Acad Radiol, 2025, 32(3): 1241-1251. DOI: 10.1016/j.acra.2024.09.054.
[13]
YI X, WANG G L, MA R, et al. Efficacy of different cut-off values of Kaiser score in MRI diagnosis of breast lesions[J]. J Mol Imag, 2021, 44(6): 911-916. DOI: 10.12122/j.issn.1674-4500.2021.06.05.
[14]
PÖTSCH N, KORAJAC A, STELZER P, et al. Breast MRI: does a clinical decision algorithm outweigh reader experience [J]. Eur Radiol, 2022, 32(10): 6557-6564. DOI: 10.1007/s00330-022-09015-8.
[15]
WANG Q B, FU F L, CHEN Y, et al. Application of the Kaiser score by MRI in patients with breast lesions by ultrasound and mammography[J]. Diagn Interv Radiol, 2022, 28(4): 322-328. DOI: 10.5152/dir.2022.201075.
[16]
WENGERT G J, PIPAN F, ALMOHANNA J, et al. Impact of the Kaiser score on clinical decision-making in BI-RADS 4 mammographic calcifications examined with breast MRI[J]. Eur Radiol, 2020, 30(3): 1451-1459. DOI: 10.1007/s00330-019-06444-w.
[17]
JAJODIA A, SINDHWANI G, PASRICHA S, et al. Application of the Kaiser score to increase diagnostic accuracy in equivocal lesions on diagnostic mammograms referred for MR mammography[J/OL]. Eur J Radiol, 2021, 134: 109413 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/33290973/. DOI: 10.1016/j.ejrad.2020.109413.
[18]
ISTOMIN A, MASARWAH A, VANNINEN R, et al. Diagnostic performance of the Kaiser score for characterizing lesions on breast MRI with comparison to a multiparametric classification system[J/OL]. Eur J Radiol, 2021, 138: 109659 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/33752000/. DOI: 10.1016/j.ejrad.2021.109659.
[19]
FENG L L, FENG X H, YAN R, et al. Study on the diagnostic efficacy of Kaiser scoring system based on multi-parameter MRI in breast lesions[J]. Chin J CT MRI, 2023, 21(3): 93-95. DOI: 10.3969/j.issn.1672-5131.2023.03.034.
[20]
CLOETE D J, MINNE C, SCHOUB P K, et al. Magnetic resonance imaging of fibroadenoma-like lesions and correlation with Breast Imaging-Reporting and Data System and Kaiser scoring system[J/OL]. SA J Radiol, 2018, 22(2): 1532 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/31754520/. DOI: 10.4102/sajr.v22i2.1532.
[21]
DIETZEL M, BERNATHOVA M, CLAUSER P, et al. Added value of clinical decision rules for the management of enhancing breast MRI lesions: a systematic comparison of the Kaiser score and the Göttingen score[J/OL]. Eur J Radiol, 2023, 169: 111185 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/37939606/. DOI: 10.1016/j.ejrad.2023.111185.
[22]
GUO Z Z, ZHANG B, LEI Z, et al. Diagnostic value of the Kaiser score for US BI-RADS 4A lesions of breast and potential to avoid unnecessary biopsies[J]. J Xi'an Jiaotong Univ Med Sci, 2025, 46(2): 304-309. DOI: 10.7652/jdyxb202502016.
[23]
YANG Z X, ZHAO X, TAN S F, et al. Study on the differential diagnostic efficacy of Kaiser score and apparent diffusion coefficient values for benign and malignant breast lesions during lactation[J]. Chin J Magn Reson Imaging, 2024, 15(6): 87-93. DOI: 10.12015/issn.1674-8034.2024.06.013.
[24]
MILOS R I, PIPAN F, KALOVIDOURI A, et al. The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams[J]. Eur Radiol, 2020, 30(11): 6052-6061. DOI: 10.1007/s00330-020-06945-z.
[25]
ASLAN O, OKTAY A. Diagnostic accuracy of the breast MRI Kaiser score in suspected architectural distortions and its comparison with mammography[J/OL]. Sci Rep, 2024, 14: 447 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/38172557/. DOI: 10.1038/s41598-023-50798-7.
[26]
ERKAN M, OZCAN S G G. Diagnostic performance of Kaiser score for characterization of breast lesions on modified abbreviated breast MRI and comparison with full-protocol breast MRI[J/OL]. J Clin Med, 2025, 14(1): 264 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/39797346/. DOI: 10.3390/jcm14010264.
[27]
PÖTSCH N, CLAUSER P, KAPETAS P, et al. Enhancing the Kaiser score for lesion characterization in unenhanced breast MRI[J/OL]. Eur J Radiol, 2024, 176: 111520 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/38820953/. DOI: 10.1016/j.ejrad.2024.111520.
[28]
KARABULUT U E, CELIK YABUL F, POLAT Y B, et al. Contrıbutıon of Kaıser score in non-mass enhanced breast lesions[J/OL]. Eur J Radiol, 2025, 185: 112002 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/39970546/. DOI: 10.1016/j.ejrad.2025.112002.
[29]
ZHANG B, FENG L L, WANG L, et al. Kaiser score for diagnosis of breast lesions presenting as non-mass enhancement on MRI[J]. J South Med Univ, 2020, 40(4): 562-566. DOI: 10.12122/j.issn.1673-4254.2020.04.18.
[30]
ZHANG B, GUO Z Z, LEI Z, et al. Kaiser score diagnosis of breast MRI lesions: Factors associated with false-negative and false-positive results[J/OL]. Eur J Radiol, 2024, 178: 111641 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/39053308/. DOI: 10.1016/j.ejrad.2024.111641.
[31]
HORVAT J V, DURANDO M, MILANS S, et al. Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis[J]. Eur Radiol, 2018, 28(6): 2516-2524. DOI: 10.1007/s00330-017-5202-4.
[32]
QU N, LUO Y H, YU T, et al. Differentiation between pure mucinous breast carcinomas and fibroadenomas with strong high-signal intensity on T2-weighted images from dynamic contrast-enhanced magnetic resonance imaging[J]. Breast Care, 2018, 13(1): 32-37. DOI: 10.1159/000479955.
[33]
ZHOU X Z, LIU L H, HE S, et al. Diagnostic value of Kaiser score combined with breast vascular assessment from breast MRI for the characterization of breast lesions[J/OL]. Front Oncol, 2023, 13: 1165405 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/37483510/. DOI: 10.3389/fonc.2023.1165405.
[34]
JIA M, WANG L S, WU Z S, et al. Evaluation of diagnostic efficacy of Kaiser score and adjacent vascular sign in breast lesions[J]. Anhui Med J, 2024, 45(11): 1385-1389. DOI: 10.3969/j.issn.1000-0399.2024.11.009.
[35]
DU L, ZHANG R X, XU K P, et al. Clinical value of Kaiser score in diagnosis of sub-centimeter breast masses of BI-RADS Category 4 by MRI[J]. Chin Imag J Integr Tradit West Med, 2023, 21(6): 656-662. DOI: 10.3969/j.issn.1672-0512.2023.06.012.
[36]
AVDAN ASLAN A, GÜLTEKIN S. Diagnostic performance of Kaiser score in patients with newly diagnosed breast cancer: Factors associated with false-negative results[J/OL]. Eur J Radiol, 2023, 164: 110864 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/37209464/. DOI: 10.1016/j.ejrad.2023.110864.
[37]
WOODHAMS R, KAKITA S, HATA H, et al. Diffusion-weighted imaging of mucinous carcinoma of the breast: evaluation of apparent diffusion coefficient and signal intensity in correlation with histologic findings[J]. AJR Am J Roentgenol, 2009, 193(1): 260-266. DOI: 10.2214/AJR.08.1670.
[38]
PARTRIDGE S C, DEMARTINI W B, KURLAND B F, et al. Quantitative diffusion-weighted imaging as an adjunct to conventional breast MRI for improved positive predictive value[J]. AJR Am J Roentgenol, 2009, 193(6): 1716-1722. DOI: 10.2214/AJR.08.2139.
[39]
PAN J L, LI X H, CHEN X J, et al. A comparison of the Kaiser score and apparent diffusion coefficient mapping in the assessment of breast lesions[J]. Chin J Magn Reson Imaging, 2022, 13(6): 108-111, 116. DOI: 10.12015/issn.1674-8034.2022.06.021.
[40]
REN X M, LIU X C, DAI T Z, et al. Comparative assessment of MRI BI-RADS 4 breast lesions with Kaiser score and apparent diffusion coefficient value[J]. Chin J Magn Reson Imaging, 2022, 13(9): 25-29, 34. DOI: 10.12015/issn.1674-8034.2022.09.005.
[41]
AN Y Y, MAO G Q, AO W Q, et al. Can DWI provide additional value to Kaiser score in evaluation of breast lesions[J]. Eur Radiol, 2022, 32(9): 5964-5973. DOI: 10.1007/s00330-022-08674-x.
[42]
DIETZEL M, KRUG B, CLAUSER P, et al. A multicentric comparison of apparent diffusion coefficient mapping and the Kaiser score in the assessment of breast lesions[J]. Invest Radiol, 2021, 56(5): 274-282. DOI: 10.1097/RLI.0000000000000739.
[43]
COSKUN BILGE A, AYDIN H. Assessment of the contribution of the ADC value to the Kaiser score in the differential diagnosis of breast lesions with non-mass enhancement morphology on MRI[J/OL]. Eur J Radiol, 2024, 181: 111713 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/39241300/. DOI: 10.1016/j.ejrad.2024.111713.
[44]
LU L, GUO Y F, ZHAO X. Value of synthetic MRI combined with Kaiser score in differential diagno-sis of BI-RADS 4 category breast lesions[J]. J Zhengzhou Univ Med Sci, 2023, 58(6): 824-828. DOI: 10.13705/j.issn.1671-6825.2023.03.004.
[45]
GRIPPO C, JAGMOHAN P, HELBICH T H, et al. Correct determination of the enhancement curve is critical to ensure accurate diagnosis using the Kaiser score as a clinical decision rule for breast MRI[J/OL]. Eur J Radiol, 2021, 138: 109630 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/33744507/. DOI: 10.1016/j.ejrad.2021.109630.
[46]
PÖTSCH N, VATTERONI G, CLAUSER P, et al. Using the Kaiser Score as a clinical decision rule for breast lesion classification: Does computer-assisted curve type analysis improve diagnosis [J]. Eur J Radiol, 2024, 170: 111271. DOI: 10.1016/j.ejrad.2023.111271.
[47]
CHEN Z W, ZHAO Y F, LIU H R, et al. Assessment of breast lesions by the Kaiser score for differential diagnosis on MRI: the added value of ADC and machine learning modeling[J]. Eur Radiol, 2022, 32(10): 6608-6618. DOI: 10.1007/s00330-022-08899-w.
[48]
GAO W X, SHENG M H, XIAO J Y, et al. Value of a clinical-multiparametric MRI diagnostic model based on Kaiser score in the differential diagnosis of benign and malignant breast lesions[J]. Chin J Magn Reson Imaging, 2024, 15(8): 117-123. DOI: 10.12015/issn.1674-8034.2024.08.018.
[49]
YI X, WANG Y A, LIU F, et al. Development and validation of a predictive model for the diagnosis of breast MRI masses based on the Kaiser score[J]. Chin J Magn Reson Imaging, 2023, 14(5): 96-103. DOI: 10.12015/issn.1674-8034.2023.05.018.
[50]
YI X, WANG G L, YANG Y, et al. Development and validation of a diagnostic model for enhancing lesions on breast MRI: based on Kaiser score[J]. Acad Radiol, 2025, 32(2): 664-680. DOI: 10.1016/j.acra.2024.09.028.
[51]
LIANG Y T, WEI Z T, DAI Y, et al. An interpretable AI system reduces false-positive MRI diagnoses by stratifying high-risk breast lesions[J/OL]. Nat Commun, 2026, 17(1): 2263 [2026-05-13]. https://pubmed.ncbi.nlm.nih.gov/41629316/. DOI: 10.1038/s41467-026-69212-7.
[52]
EGHTEDARI M, CHONG A, RAKOW-PENNER R, et al. Current status and future of BI-RADS in multimodality imaging, from the AJR special series on radiology reporting and data systems[J]. AJR Am J Roentgenol, 2021, 216(4): 860-873. DOI: 10.2214/AJR.20.24894.

PREV Research advances in multimodal MRI for evaluating the efficacy of neoadjuvant therapy in breast cancer
NEXT Research progress of CT and MRI radiomics in predicting postoperative recurrence of hepatocellular carcinoma
  



Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn